This quarter the initial public offering (IPO) market set records for the amount of money raised while other financings dropped slightly from previous quarters. Much of the bonanza came from the East: Chinese biotechs increasingly contributed to the global picture. A notable number of venture capital investments (3 out of the top 10) went into precision medicine diagnostics, a sector traditionally lacking funding. Two startups developing RNA-targeted therapies were among the top 10 deals.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Q218—public flotation jackpot. Nat Biotechnol 36, 786 (2018). https://doi.org/10.1038/nbt.4249
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4249
